In the past decade, there have been major advances in the treatment of the blood cancer Multiple Myeloma (MM). The introduction of novel agents such as immune-modifying agents (IMIDs), proteasome inhibitors, monoclonal antibodies, with or without stem cell transplantation, has resulted in significantly improved patient survival. Meanwhile, the increased understanding of MM tumor biology has provided a rationale for new combinations of drugs and risk-adapted and individualized treatments to further improve patient management.

 ACCREDITATION

10,5 CME for Physicians, Biologists, Nurses, Biomedical Laboratory Technicians

For more information please visit the official event page.